Zhejiang Wecome Pharmaceutical Co., Ltd. Class A

Zhejiang Wecome Pharmaceutical Co., Ltd. Class A

SSZSE:300878
30.58
CNY
-0.75
(-2.39%)
-0.90EPS
4.37BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.24
1.41
1.91
2.6
3.75
5.3
5.91
5.17
4.39
3.71
3.48
2.45
1.56
1.77
Basic EPS, GAAP
0.18
0.19
0.46
0.74
0.88
0.81
1.16
1.13
0.67
0.34
-0.06
-1.03
-1.57
-0.89
Free Cash Flow per Basic Share
0.13
0.05
-0.08
- -
-0.12
-0.62
-0.02
-0.91
-1.66
-0.2
-0.54
-1.08
- -
- -
Dividend per Share
0.01
0.01
- -
- -
- -
0.01
0.05
0.07
0.56
0.32
0.05
0.31
0.2
0.05
Book Value per Share
0.31
0.72
1.2
1.94
2.82
3.63
4.79
9.54
9.65
9.65
9.6
8
6.29
6.13
Tangible Book Value per Share
0.28
0.69
1.17
1.68
2.56
3.36
4.5
9.33
9.26
9.21
9.17
7.69
6.08
5.92
Basic Weighted Avg Shares
109
109
108
109
108
109
109
120
144
144
149
143
145
143
Sales/Revenue/Turnover
135
153
208
282
407
578
642
623
633
532
520
351
225
252
Operating Margin (%)
19.49
25.51
27.54
27.68
26.72
18.82
23.45
25.99
16.47
11.56
-4.27
-41.2
-38
-2.89
Depreciation Expense
4
4
5
- -
10
11
12
12
27
42
47
68
63
- -
Net Income, GAAP
20
21
50
81
95
88
126
136
96
49
-9
-147
-227
-127
Effective Tax Rate (%)
18.47
26.7
13.51
14.5
14.45
15.11
14.65
14.49
3.48
21.64
- -
- -
- -
- -
Profit Margin (%)
14.62
13.52
24.08
28.66
23.41
15.2
19.63
21.81
15.25
9.17
-1.72
-41.98
-100.92
-50.16
Working Capital
5
24
56
104
142
143
251
767
638
621
606
376
198
132
LT Debt
- -
- -
- -
- -
- -
42
136
26
20
50
163
192
92
5
Total Equity
34
78
130
211
306
394
520
1,384
1,409
1,411
1,408
1,174
924
901
Return on Invested Capital (%)
- -
39.64
44.63
35.66
32.06
21.96
21.89
12.82
6.57
3.19
- -
- -
- -
- -
Return on Capital (%)
- -
35.44
47.76
47.5
34.95
22.85
22.24
12.82
6.72
3.25
- -
- -
- -
- -
Return on Common Equity (%)
- -
37.04
48.04
47.43
36.82
25.08
27.58
14.29
6.95
3.49
-0.64
-11.57
-21.99
-12.91

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
148
229
229
LT Borrowings
90
4
4
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
145
145
145
Market Capitalization
3,982
4,681
4,367

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
430
432
445
Cash, Cash Equivalents & STI
192
195
183
Accounts Receivable, Net
139
140
151
Inventories
55
55
58
Total Current Liabilities
221
313
313
Payables & Accruals
- -
- -
- -
ST Debt
148
229
229
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.8%
-7.25%
-21.31%
Free Cash Flow
- -
41.45%
-99.95%
Net Income, GAAP
152.68%
280.78%
54.21%
Sales/Revenue/Turnover
4.52%
-16.98%
-35.86%
Total Cash Common Dividend
- -
260.51%
-35.99%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
200
97
74
-20
351
2025
70
45
- -
74
225
2026
70
56
52
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
-0.07
0.21
-1.32
-1.03
2025
-0.07
-0.38
- -
-0.73
-1.57
2026
0.01
-0.17
-0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.28
0.01
0.02
0.31
2025
0.02
0.15
- -
0.02
0.2
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Yang Liu
Full Time Employees
535
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 2, Songsong Road Lishui ZH China 323000
IPO Date
Aug 24, 2020
Website
zjwk.com
Business
Zhejiang Wecome Pharmaceutical Company Limited is a high-tech enterprise specializing in the comprehensive processes of pharmaceutical research, development, manufacturing, and distribution within China. The company's operations encompass both modern Western pharmaceuticals and traditional Chinese medicines. Its product portfolio includes a diverse range of items such as silver yellow drop pills, yimucao softgels, and roxithromycin softgels. These medical preparations are offered in various forms, including tablets, hard capsules, softgels, granules, and pills. Since its founding in 2000, the company, headquartered in Lishui, China, has also established a presence in the pharmaceutical retail sector through its distribution networks. Notably, the firm initiated a Phase III clinical trial for its Huangjia Ruan Gan Granules, a Class 1.1 new traditional Chinese medicine for liver fibrosis, in September 2025. The company has been listed on the Shenzhen Stock Exchange's Growth Enterprise Market since August 2020.